Danish firm Santaris Pharma AS racked up another multimillion dollar deal to develop drugs based on its locked nucleic acid (LNA) platform targeting microRNAs and messenger RNAs, this time with London-based Shire plc for drugs to treat rare genetic disorders. (BioWorld International) Read More
